Company Description
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.
It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Country | Switzerland |
| Founded | 1895 |
| IPO Date | Nov 18, 1991 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 76,057 |
| CEO | Vasant Narasimhan |
Contact Details
Address: Lichtstrasse 35 Basel, 4056 Switzerland | |
| Phone | 41 61 324 1111 |
| Website | novartis.com |
Stock Details
| Ticker Symbol | NVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001114448 |
| CUSIP Number | 66987V109 |
| ISIN Number | US66987V1098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer |
| Harry Kirsch | Chief Financial Officer |
| Victor Bulto | President of US |
| Dr. Patrick Horber M.D. | President of International |
| Dr. Steffen Lang Ph.D. | President of Operations |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Sloan Simpson | Global Head of Investor Relations |
| Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk and Compliance Officer |
| Karen L. Hale | Chief Legal Officer |
| Dr. Robert Kowalski Pharm.D. | Chief People and Organization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 25, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | 6-K | Report of foreign issuer |
| Oct 29, 2024 | 6-K | Report of foreign issuer |
| Sep 18, 2024 | 6-K | Report of foreign issuer |
| Sep 17, 2024 | 424B5 | Filing |
| Sep 17, 2024 | 6-K | Report of foreign issuer |
| Sep 16, 2024 | FWP | Free Writing Prospectus |
| Sep 16, 2024 | 424B5 | Filing |
| Sep 16, 2024 | F-3ASR | Filing |
| Aug 12, 2024 | 144 | Filing |